Skip to content
ARVN·Nasdaq·US

Arvinas

Arvinas is a clinical-stage biotechnology company that develops PROTAC protein degraders, a class of therapeutics designed to use the body's natural protein disposal system to degrade disease-causing proteins. It is advancing clinical programs in oncology and neurology, including vepdegestrant, which has an FDA-accepted NDA, and ARV-102, ARV-806, ARV-393 and ARV-027.

Source: SEC 10-K Feb 24, 2026

Recent Activity

Updated Oct 10, 2026
–Arvinas presented new Phase 1 clinical trial data for ARV-102 in Parkinson's disease patients, showing improvements in an objective measure of impaired eye movement linked to the disease.
–The data revealed a correlation between reductions in LRRK2 biomarker levels and these oculomotor improvements.

Past updates are part of the Pro plan.

Thematic Position

ARVN

Relationship Groups

Partners2
Licensing3
Competitors7

Relationship details are part of the Pro plan.

Ended Relationships

8 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

procurement restrictionnational security
BIOSECURE Act restricts U.S. government procurement from Chinese biotechnology companies of concern
SEC 10-KFeb 24, 2026

The full regulatory passage is part of the Pro plan.

3 more · Regulatory and geopolitical insights are part of the Pro plan.